- In late April 2026, Medtronic reported progress across its Affera cardiac arrhythmia portfolio, including promising ventricular tachycardia and atrial fibrillation data, an FDA Breakthrough Device Designation for the Sphere-9 catheter in VT, and new global trial enrollments, while also securing CE Mark for its Stealth AXiS surgical system for spine and cranial procedures.
- These regulatory wins and early clinical results highlight Medtronic’s push into next-generation arrhythmia ablation and integrated surgical robotics, potentially strengthening its position in complex cardiovascular and neurosurgical care.
- We’ll now explore how the FDA Breakthrough Device status for Sphere-9 might influence Medtronic’s investment narrative and long-term growth assumptions.
Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI…
